Clearmind investigators cite positive early safety, tolerability for CMND-100 in Phase I/IIa AUD trial

Clearmind flagged positive early feedback from investigators in its ongoing first-in-human Phase I/IIa trial of CMND-100 (MEAI) for alcohol use disorder.

Investigators cited a non-hallucinogenic profile that could support a simpler, more scalable treatment model than classical psychedelics.

Early readouts indicated no meaningful adverse effects or cardiac safety concerns observed to date.

Recruitment was progressing despite strict healthy-volunteer eligibility criteria.